Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)-Reference-Cited by-同舟云学术

Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)

Published:2018-05 Issue:5 Volume:24 Page:923-929
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Jung Sung-Hoon,Lee Je-Jung,Kim Jin Seok,Min Chang-Ki,Kim Kihyun,Choi Yunsuk,Eom Hyeon-Seok,Joo Young Don,Kim Sung-Hyun,Kwak Jae-Yong,Kang Hye Jin,Lee Jae Hoon,Lee Ho Sup,Mun Yeung-Chul,Moon Joon Ho,Sohn Sang Kyun,Park Seong Kyu,Park Yong,Shin Ho-Jin,Yoon Sung-Soo

Funder

Korea Otsuka: donation of busulfan

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference34 articles.

1. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma;McElwain;Lancet,1983

2. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003

3. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials;Koreth;Biol Blood Marrow Transplant,2007

4. Autologous transplantation and maintenance therapy in multiple myeloma;Palumbo;N Engl J Med,2014

5. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial;Gay;Lancet Oncol,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress in Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma;Advances in Clinical Medicine;2023

2. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea;The Korean Journal of Internal Medicine;2021-11-01

3. Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen;Leukemia & Lymphoma;2020-08-31

4. Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma;Hematological Oncology;2020-07-29

5. Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis;Leukemia & Lymphoma;2020-06-25